nodes	percent_of_prediction	percent_of_DWPC	metapath
Procarbazine—CYP1B1—esophageal cancer	0.504	1	CbGaD
Procarbazine—XDH—Carboplatin—esophageal cancer	0.216	0.539	CbGbCtD
Procarbazine—XDH—Cisplatin—esophageal cancer	0.184	0.461	CbGbCtD
Procarbazine—Peroneal nerve palsy—Capecitabine—esophageal cancer	0.00297	0.0436	CcSEcCtD
Procarbazine—Metastatic neoplasm—Cisplatin—esophageal cancer	0.00285	0.0417	CcSEcCtD
Procarbazine—Apprehension—Cisplatin—esophageal cancer	0.00285	0.0417	CcSEcCtD
Procarbazine—Pulmonary toxicity—Cisplatin—esophageal cancer	0.0024	0.0352	CcSEcCtD
Procarbazine—Azoospermia—Cisplatin—esophageal cancer	0.00203	0.0297	CcSEcCtD
Procarbazine—Acute leukaemia—Cisplatin—esophageal cancer	0.00191	0.028	CcSEcCtD
Procarbazine—Papilloedema—Cisplatin—esophageal cancer	0.00172	0.0252	CcSEcCtD
Procarbazine—XDH—Effects of Nitric Oxide—NOS2—esophageal cancer	0.00146	0.0584	CbGpPWpGaD
Procarbazine—Herpes virus infection—Capecitabine—esophageal cancer	0.00145	0.0212	CcSEcCtD
Procarbazine—CYP1B1—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00138	0.0551	CbGpPWpGaD
Procarbazine—Pulmonary toxicity—Methotrexate—esophageal cancer	0.00132	0.0193	CcSEcCtD
Procarbazine—Slurred speech—Cisplatin—esophageal cancer	0.00122	0.0179	CcSEcCtD
Procarbazine—XDH—Oxidative Stress—NFE2L2—esophageal cancer	0.0012	0.0477	CbGpPWpGaD
Procarbazine—XDH—Effects of Nitric Oxide—NOS3—esophageal cancer	0.00118	0.0469	CbGpPWpGaD
Procarbazine—Infertility—Methotrexate—esophageal cancer	0.00115	0.0168	CcSEcCtD
Procarbazine—Azoospermia—Methotrexate—esophageal cancer	0.00111	0.0163	CcSEcCtD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor Pathway—ALDH3A1—esophageal cancer	0.00105	0.0417	CbGpPWpGaD
Procarbazine—Ibuprofen—BCL2—esophageal cancer	0.001	0.437	CrCbGaD
Procarbazine—Hoarseness—Capecitabine—esophageal cancer	0.000915	0.0134	CcSEcCtD
Procarbazine—Febrile neutropenia—Cisplatin—esophageal cancer	0.000907	0.0133	CcSEcCtD
Procarbazine—Optic neuritis—Cisplatin—esophageal cancer	0.000887	0.013	CcSEcCtD
Procarbazine—Ascites—Capecitabine—esophageal cancer	0.000885	0.013	CcSEcCtD
Procarbazine—XDH—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.00088	0.0351	CbGpPWpGaD
Procarbazine—XDH—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.00088	0.0351	CbGpPWpGaD
Procarbazine—Osteonecrosis—Methotrexate—esophageal cancer	0.000804	0.0118	CcSEcCtD
Procarbazine—Balance disorder—Capecitabine—esophageal cancer	0.000736	0.0108	CcSEcCtD
Procarbazine—CYP1B1—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.000733	0.0292	CbGpPWpGaD
Procarbazine—XDH—Oxidative Stress—HMOX1—esophageal cancer	0.000711	0.0284	CbGpPWpGaD
Procarbazine—Pericarditis—Methotrexate—esophageal cancer	0.000692	0.0102	CcSEcCtD
Procarbazine—XDH—Nucleotide metabolism—TYMP—esophageal cancer	0.000691	0.0276	CbGpPWpGaD
Procarbazine—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.000676	0.00992	CcSEcCtD
Procarbazine—Febrile neutropenia—Capecitabine—esophageal cancer	0.000669	0.0098	CcSEcCtD
Procarbazine—XDH—Oxidative Stress—SOD2—esophageal cancer	0.000665	0.0266	CbGpPWpGaD
Procarbazine—Infection—Carboplatin—esophageal cancer	0.000659	0.00967	CcSEcCtD
Procarbazine—Haematemesis—Capecitabine—esophageal cancer	0.000579	0.00849	CcSEcCtD
Procarbazine—Dysarthria—Cisplatin—esophageal cancer	0.000577	0.00846	CcSEcCtD
Procarbazine—Hearing impaired—Cisplatin—esophageal cancer	0.000573	0.0084	CcSEcCtD
Procarbazine—Thrombosis—Capecitabine—esophageal cancer	0.000568	0.00833	CcSEcCtD
Procarbazine—Pain—Carboplatin—esophageal cancer	0.000568	0.00832	CcSEcCtD
Procarbazine—Haemoptysis—Capecitabine—esophageal cancer	0.000543	0.00797	CcSEcCtD
Procarbazine—Pleural effusion—Capecitabine—esophageal cancer	0.000525	0.0077	CcSEcCtD
Procarbazine—Body temperature increased—Carboplatin—esophageal cancer	0.000525	0.00769	CcSEcCtD
Procarbazine—CYP1B1—Endogenous sterols—CYP19A1—esophageal cancer	0.000516	0.0206	CbGpPWpGaD
Procarbazine—Neuropathy—Cisplatin—esophageal cancer	0.000512	0.00751	CcSEcCtD
Procarbazine—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000503	0.00738	CcSEcCtD
Procarbazine—CYP1B1—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000501	0.02	CbGpPWpGaD
Procarbazine—Febrile neutropenia—Methotrexate—esophageal cancer	0.000498	0.0073	CcSEcCtD
Procarbazine—Petechiae—Capecitabine—esophageal cancer	0.000489	0.00717	CcSEcCtD
Procarbazine—Dysphonia—Capecitabine—esophageal cancer	0.000489	0.00717	CcSEcCtD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.000455	0.0182	CbGpPWpGaD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.000455	0.0182	CbGpPWpGaD
Procarbazine—Atenolol—ABCB1—esophageal cancer	0.000446	0.195	CrCbGaD
Procarbazine—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000444	0.0177	CbGpPWpGaD
Procarbazine—Deafness—Cisplatin—esophageal cancer	0.000443	0.00649	CcSEcCtD
Procarbazine—CYP1B1—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000442	0.0176	CbGpPWpGaD
Procarbazine—Haemolytic anaemia—Cisplatin—esophageal cancer	0.000439	0.00643	CcSEcCtD
Procarbazine—CYP1B1—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000438	0.0175	CbGpPWpGaD
Procarbazine—Nocturia—Capecitabine—esophageal cancer	0.000434	0.00636	CcSEcCtD
Procarbazine—Haematemesis—Methotrexate—esophageal cancer	0.000431	0.00632	CcSEcCtD
Procarbazine—Dysarthria—Capecitabine—esophageal cancer	0.000425	0.00624	CcSEcCtD
Procarbazine—Hearing impaired—Capecitabine—esophageal cancer	0.000423	0.0062	CcSEcCtD
Procarbazine—CYP1B1—Tryptophan metabolism—ALDH2—esophageal cancer	0.000416	0.0166	CbGpPWpGaD
Procarbazine—XDH—Selenium Micronutrient Network—PTGS1—esophageal cancer	0.000412	0.0165	CbGpPWpGaD
Procarbazine—Ibuprofen—PTGS1—esophageal cancer	0.00041	0.179	CrCbGaD
Procarbazine—Melaena—Capecitabine—esophageal cancer	0.000393	0.00576	CcSEcCtD
Procarbazine—Pleural effusion—Methotrexate—esophageal cancer	0.000391	0.00573	CcSEcCtD
Procarbazine—CYP1B1—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000387	0.0155	CbGpPWpGaD
Procarbazine—Neuropathy—Capecitabine—esophageal cancer	0.000378	0.00554	CcSEcCtD
Procarbazine—Petechiae—Methotrexate—esophageal cancer	0.000364	0.00534	CcSEcCtD
Procarbazine—CYP1B1—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00036	0.0144	CbGpPWpGaD
Procarbazine—CYP1B1—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000347	0.0139	CbGpPWpGaD
Procarbazine—Pancreatitis—Cisplatin—esophageal cancer	0.000336	0.00492	CcSEcCtD
Procarbazine—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000334	0.0049	CcSEcCtD
Procarbazine—Sweating increased—Cisplatin—esophageal cancer	0.000333	0.00489	CcSEcCtD
Procarbazine—Photosensitivity—Capecitabine—esophageal cancer	0.000333	0.00488	CcSEcCtD
Procarbazine—Vascular purpura—Capecitabine—esophageal cancer	0.000326	0.00479	CcSEcCtD
Procarbazine—Deafness—Capecitabine—esophageal cancer	0.000326	0.00479	CcSEcCtD
Procarbazine—Pancytopenia—Cisplatin—esophageal cancer	0.000325	0.00477	CcSEcCtD
Procarbazine—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000323	0.00474	CcSEcCtD
Procarbazine—Dysarthria—Methotrexate—esophageal cancer	0.000317	0.00464	CcSEcCtD
Procarbazine—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000316	0.0126	CbGpPWpGaD
Procarbazine—CYP1B1—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000312	0.0125	CbGpPWpGaD
Procarbazine—Purpura—Capecitabine—esophageal cancer	0.000303	0.00444	CcSEcCtD
Procarbazine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000299	0.00439	CcSEcCtD
Procarbazine—Lethargy—Capecitabine—esophageal cancer	0.000298	0.00437	CcSEcCtD
Procarbazine—Stomatitis—Cisplatin—esophageal cancer	0.000298	0.00436	CcSEcCtD
Procarbazine—CYP1B1—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000297	0.0118	CbGpPWpGaD
Procarbazine—Melaena—Methotrexate—esophageal cancer	0.000292	0.00429	CcSEcCtD
Procarbazine—Diplopia—Capecitabine—esophageal cancer	0.000292	0.00428	CcSEcCtD
Procarbazine—XDH—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000281	0.0112	CbGpPWpGaD
Procarbazine—Ataxia—Capecitabine—esophageal cancer	0.000275	0.00403	CcSEcCtD
Procarbazine—Coma—Methotrexate—esophageal cancer	0.000274	0.00401	CcSEcCtD
Procarbazine—CYP1B1—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000273	0.0109	CbGpPWpGaD
Procarbazine—Gynaecomastia—Methotrexate—esophageal cancer	0.000268	0.00393	CcSEcCtD
Procarbazine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000263	0.00386	CcSEcCtD
Procarbazine—CYP1B1—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000257	0.0102	CbGpPWpGaD
Procarbazine—Flushing—Cisplatin—esophageal cancer	0.000254	0.00373	CcSEcCtD
Procarbazine—Dysphagia—Capecitabine—esophageal cancer	0.000252	0.0037	CcSEcCtD
Procarbazine—Photosensitivity—Methotrexate—esophageal cancer	0.000248	0.00363	CcSEcCtD
Procarbazine—Angina pectoris—Capecitabine—esophageal cancer	0.000246	0.0036	CcSEcCtD
Procarbazine—Sweating increased—Capecitabine—esophageal cancer	0.000246	0.0036	CcSEcCtD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.000246	0.00981	CbGpPWpGaD
Procarbazine—Arrhythmia—Cisplatin—esophageal cancer	0.000245	0.00359	CcSEcCtD
Procarbazine—CYP1B1—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000243	0.00971	CbGpPWpGaD
Procarbazine—Alopecia—Cisplatin—esophageal cancer	0.000242	0.00355	CcSEcCtD
Procarbazine—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00024	0.00957	CbGpPWpGaD
Procarbazine—Pancytopenia—Capecitabine—esophageal cancer	0.00024	0.00351	CcSEcCtD
Procarbazine—CYP1B1—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000237	0.00945	CbGpPWpGaD
Procarbazine—CYP1B1—Biological oxidations—ADH7—esophageal cancer	0.000235	0.00936	CbGpPWpGaD
Procarbazine—Ibuprofen—PTGS2—esophageal cancer	0.000234	0.102	CrCbGaD
Procarbazine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00023	0.00338	CcSEcCtD
Procarbazine—Pneumonia—Capecitabine—esophageal cancer	0.000226	0.00332	CcSEcCtD
Procarbazine—Tremor—Cisplatin—esophageal cancer	0.000223	0.00328	CcSEcCtD
Procarbazine—Lethargy—Methotrexate—esophageal cancer	0.000222	0.00325	CcSEcCtD
Procarbazine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000221	0.00323	CcSEcCtD
Procarbazine—Anaemia—Cisplatin—esophageal cancer	0.00022	0.00323	CcSEcCtD
Procarbazine—Stomatitis—Capecitabine—esophageal cancer	0.000219	0.00322	CcSEcCtD
Procarbazine—Jaundice—Capecitabine—esophageal cancer	0.000219	0.00322	CcSEcCtD
Procarbazine—Haematuria—Capecitabine—esophageal cancer	0.000215	0.00315	CcSEcCtD
Procarbazine—Leukopenia—Cisplatin—esophageal cancer	0.000214	0.00313	CcSEcCtD
Procarbazine—Epistaxis—Capecitabine—esophageal cancer	0.000212	0.00311	CcSEcCtD
Procarbazine—Convulsion—Cisplatin—esophageal cancer	0.000207	0.00303	CcSEcCtD
Procarbazine—CYP1B1—Biological oxidations—ADH1B—esophageal cancer	0.000206	0.00821	CbGpPWpGaD
Procarbazine—Ataxia—Methotrexate—esophageal cancer	0.000204	0.003	CcSEcCtD
Procarbazine—Myalgia—Cisplatin—esophageal cancer	0.000203	0.00298	CcSEcCtD
Procarbazine—Haemoglobin—Capecitabine—esophageal cancer	0.000203	0.00298	CcSEcCtD
Procarbazine—Anxiety—Cisplatin—esophageal cancer	0.000202	0.00297	CcSEcCtD
Procarbazine—Haemorrhage—Capecitabine—esophageal cancer	0.000202	0.00296	CcSEcCtD
Procarbazine—Ibuprofen—ABCB1—esophageal cancer	0.000199	0.0869	CrCbGaD
Procarbazine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000196	0.00287	CcSEcCtD
Procarbazine—Oedema—Cisplatin—esophageal cancer	0.000195	0.00285	CcSEcCtD
Procarbazine—CYP1B1—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000194	0.00776	CbGpPWpGaD
Procarbazine—Infection—Cisplatin—esophageal cancer	0.000193	0.00284	CcSEcCtD
Procarbazine—CYP1B1—Biological oxidations—CYP26A1—esophageal cancer	0.000191	0.00763	CbGpPWpGaD
Procarbazine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000191	0.00279	CcSEcCtD
Procarbazine—Tachycardia—Cisplatin—esophageal cancer	0.00019	0.00279	CcSEcCtD
Procarbazine—CYP1B1—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000189	0.00753	CbGpPWpGaD
Procarbazine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000188	0.00276	CcSEcCtD
Procarbazine—Flushing—Capecitabine—esophageal cancer	0.000187	0.00275	CcSEcCtD
Procarbazine—Eosinophilia—Methotrexate—esophageal cancer	0.000186	0.00273	CcSEcCtD
Procarbazine—Anorexia—Cisplatin—esophageal cancer	0.000186	0.00272	CcSEcCtD
Procarbazine—Pancreatitis—Methotrexate—esophageal cancer	0.000184	0.0027	CcSEcCtD
Procarbazine—Hypotension—Cisplatin—esophageal cancer	0.000182	0.00267	CcSEcCtD
Procarbazine—Chills—Capecitabine—esophageal cancer	0.000181	0.00266	CcSEcCtD
Procarbazine—Arrhythmia—Capecitabine—esophageal cancer	0.00018	0.00265	CcSEcCtD
Procarbazine—Alopecia—Capecitabine—esophageal cancer	0.000178	0.00262	CcSEcCtD
Procarbazine—Pancytopenia—Methotrexate—esophageal cancer	0.000178	0.00262	CcSEcCtD
Procarbazine—CYP1B1—Biological oxidations—GSTO1—esophageal cancer	0.000178	0.0071	CbGpPWpGaD
Procarbazine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000177	0.0026	CcSEcCtD
Procarbazine—CYP1B1—Metapathway biotransformation—GSTO1—esophageal cancer	0.000175	0.007	CbGpPWpGaD
Procarbazine—Paraesthesia—Cisplatin—esophageal cancer	0.000175	0.00256	CcSEcCtD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000173	0.0069	CbGpPWpGaD
Procarbazine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000171	0.00251	CcSEcCtD
Procarbazine—Decreased appetite—Cisplatin—esophageal cancer	0.000169	0.00248	CcSEcCtD
Procarbazine—Pneumonia—Methotrexate—esophageal cancer	0.000168	0.00247	CcSEcCtD
Procarbazine—Drowsiness—Methotrexate—esophageal cancer	0.000168	0.00246	CcSEcCtD
Procarbazine—Pain—Cisplatin—esophageal cancer	0.000166	0.00244	CcSEcCtD
Procarbazine—Tremor—Capecitabine—esophageal cancer	0.000165	0.00242	CcSEcCtD
Procarbazine—Stomatitis—Methotrexate—esophageal cancer	0.000163	0.00239	CcSEcCtD
Procarbazine—Anaemia—Capecitabine—esophageal cancer	0.000163	0.00238	CcSEcCtD
Procarbazine—Sweating—Methotrexate—esophageal cancer	0.000161	0.00235	CcSEcCtD
Procarbazine—Feeling abnormal—Cisplatin—esophageal cancer	0.00016	0.00235	CcSEcCtD
Procarbazine—Haematuria—Methotrexate—esophageal cancer	0.00016	0.00234	CcSEcCtD
Procarbazine—Epistaxis—Methotrexate—esophageal cancer	0.000158	0.00232	CcSEcCtD
Procarbazine—XDH—Selenium Micronutrient Network—PTGS2—esophageal cancer	0.000158	0.0063	CbGpPWpGaD
Procarbazine—Syncope—Capecitabine—esophageal cancer	0.000158	0.00231	CcSEcCtD
Procarbazine—Leukopenia—Capecitabine—esophageal cancer	0.000157	0.00231	CcSEcCtD
Procarbazine—Loss of consciousness—Capecitabine—esophageal cancer	0.000155	0.00227	CcSEcCtD
Procarbazine—Body temperature increased—Cisplatin—esophageal cancer	0.000154	0.00226	CcSEcCtD
Procarbazine—Cough—Capecitabine—esophageal cancer	0.000153	0.00225	CcSEcCtD
Procarbazine—Hypertension—Capecitabine—esophageal cancer	0.000152	0.00223	CcSEcCtD
Procarbazine—Haemoglobin—Methotrexate—esophageal cancer	0.000151	0.00222	CcSEcCtD
Procarbazine—Haemorrhage—Methotrexate—esophageal cancer	0.00015	0.0022	CcSEcCtD
Procarbazine—Myalgia—Capecitabine—esophageal cancer	0.00015	0.00219	CcSEcCtD
Procarbazine—Arthralgia—Capecitabine—esophageal cancer	0.00015	0.00219	CcSEcCtD
Procarbazine—Anxiety—Capecitabine—esophageal cancer	0.000149	0.00219	CcSEcCtD
Procarbazine—Dry mouth—Capecitabine—esophageal cancer	0.000146	0.00215	CcSEcCtD
Procarbazine—CYP1B1—Biological oxidations—ALDH2—esophageal cancer	0.000145	0.00578	CbGpPWpGaD
Procarbazine—Confusional state—Capecitabine—esophageal cancer	0.000145	0.00212	CcSEcCtD
Procarbazine—Oedema—Capecitabine—esophageal cancer	0.000144	0.0021	CcSEcCtD
Procarbazine—Hypersensitivity—Cisplatin—esophageal cancer	0.000143	0.0021	CcSEcCtD
Procarbazine—Infection—Capecitabine—esophageal cancer	0.000143	0.00209	CcSEcCtD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000142	0.00567	CbGpPWpGaD
Procarbazine—Shock—Capecitabine—esophageal cancer	0.000141	0.00207	CcSEcCtD
Procarbazine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000141	0.00206	CcSEcCtD
Procarbazine—Tachycardia—Capecitabine—esophageal cancer	0.00014	0.00205	CcSEcCtD
Procarbazine—Asthenia—Cisplatin—esophageal cancer	0.00014	0.00205	CcSEcCtD
Procarbazine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000139	0.00203	CcSEcCtD
Procarbazine—CYP1B1—Biological oxidations—GSTT1—esophageal cancer	0.000138	0.0055	CbGpPWpGaD
Procarbazine—Anorexia—Capecitabine—esophageal cancer	0.000137	0.00201	CcSEcCtD
Procarbazine—CYP1B1—Biological oxidations—CYP2A6—esophageal cancer	0.000136	0.00544	CbGpPWpGaD
Procarbazine—Chills—Methotrexate—esophageal cancer	0.000135	0.00198	CcSEcCtD
Procarbazine—Hypotension—Capecitabine—esophageal cancer	0.000134	0.00197	CcSEcCtD
Procarbazine—Diarrhoea—Cisplatin—esophageal cancer	0.000133	0.00195	CcSEcCtD
Procarbazine—CYP1B1—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000133	0.00531	CbGpPWpGaD
Procarbazine—Alopecia—Methotrexate—esophageal cancer	0.000133	0.00195	CcSEcCtD
Procarbazine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000131	0.00192	CcSEcCtD
Procarbazine—Insomnia—Capecitabine—esophageal cancer	0.00013	0.0019	CcSEcCtD
Procarbazine—CYP1B1—Biological oxidations—PTGS1—esophageal cancer	0.000129	0.00516	CbGpPWpGaD
Procarbazine—Paraesthesia—Capecitabine—esophageal cancer	0.000129	0.00189	CcSEcCtD
Procarbazine—Decreased appetite—Capecitabine—esophageal cancer	0.000125	0.00183	CcSEcCtD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000124	0.00496	CbGpPWpGaD
Procarbazine—Vomiting—Cisplatin—esophageal cancer	0.000124	0.00181	CcSEcCtD
Procarbazine—Fatigue—Capecitabine—esophageal cancer	0.000124	0.00181	CcSEcCtD
Procarbazine—Rash—Cisplatin—esophageal cancer	0.000123	0.0018	CcSEcCtD
Procarbazine—Pain—Capecitabine—esophageal cancer	0.000123	0.0018	CcSEcCtD
Procarbazine—Constipation—Capecitabine—esophageal cancer	0.000123	0.0018	CcSEcCtD
Procarbazine—Dermatitis—Cisplatin—esophageal cancer	0.000123	0.0018	CcSEcCtD
Procarbazine—Anaemia—Methotrexate—esophageal cancer	0.000121	0.00177	CcSEcCtD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000118	0.00472	CbGpPWpGaD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000118	0.00472	CbGpPWpGaD
Procarbazine—Feeling abnormal—Capecitabine—esophageal cancer	0.000118	0.00173	CcSEcCtD
Procarbazine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000117	0.00172	CcSEcCtD
Procarbazine—Leukopenia—Methotrexate—esophageal cancer	0.000117	0.00172	CcSEcCtD
Procarbazine—Nausea—Cisplatin—esophageal cancer	0.000116	0.0017	CcSEcCtD
Procarbazine—Cough—Methotrexate—esophageal cancer	0.000114	0.00167	CcSEcCtD
Procarbazine—Urticaria—Capecitabine—esophageal cancer	0.000114	0.00167	CcSEcCtD
Procarbazine—Abdominal pain—Capecitabine—esophageal cancer	0.000113	0.00166	CcSEcCtD
Procarbazine—Body temperature increased—Capecitabine—esophageal cancer	0.000113	0.00166	CcSEcCtD
Procarbazine—Convulsion—Methotrexate—esophageal cancer	0.000113	0.00166	CcSEcCtD
Procarbazine—Myalgia—Methotrexate—esophageal cancer	0.000111	0.00163	CcSEcCtD
Procarbazine—Arthralgia—Methotrexate—esophageal cancer	0.000111	0.00163	CcSEcCtD
Procarbazine—Confusional state—Methotrexate—esophageal cancer	0.000108	0.00158	CcSEcCtD
Procarbazine—Infection—Methotrexate—esophageal cancer	0.000106	0.00156	CcSEcCtD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000106	0.00423	CbGpPWpGaD
Procarbazine—Hypersensitivity—Capecitabine—esophageal cancer	0.000106	0.00155	CcSEcCtD
Procarbazine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000105	0.00153	CcSEcCtD
Procarbazine—XDH—Metabolism—BLVRB—esophageal cancer	0.000104	0.00413	CbGpPWpGaD
Procarbazine—XDH—Metabolism—SLC52A3—esophageal cancer	0.000104	0.00413	CbGpPWpGaD
Procarbazine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000103	0.00151	CcSEcCtD
Procarbazine—CYP1B1—Biological oxidations—CYP19A1—esophageal cancer	0.000103	0.00412	CbGpPWpGaD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000103	0.00411	CbGpPWpGaD
Procarbazine—Asthenia—Capecitabine—esophageal cancer	0.000103	0.00151	CcSEcCtD
Procarbazine—CYP1B1—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000102	0.00406	CbGpPWpGaD
Procarbazine—Anorexia—Methotrexate—esophageal cancer	0.000102	0.00149	CcSEcCtD
Procarbazine—Pruritus—Capecitabine—esophageal cancer	0.000102	0.00149	CcSEcCtD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000101	0.00402	CbGpPWpGaD
Procarbazine—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000101	0.00402	CbGpPWpGaD
Procarbazine—Hypotension—Methotrexate—esophageal cancer	9.98e-05	0.00146	CcSEcCtD
Procarbazine—Diarrhoea—Capecitabine—esophageal cancer	9.82e-05	0.00144	CcSEcCtD
Procarbazine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.73e-05	0.00143	CcSEcCtD
Procarbazine—Insomnia—Methotrexate—esophageal cancer	9.66e-05	0.00142	CcSEcCtD
Procarbazine—Paraesthesia—Methotrexate—esophageal cancer	9.59e-05	0.00141	CcSEcCtD
Procarbazine—Somnolence—Methotrexate—esophageal cancer	9.5e-05	0.00139	CcSEcCtD
Procarbazine—Dizziness—Capecitabine—esophageal cancer	9.49e-05	0.00139	CcSEcCtD
Procarbazine—Decreased appetite—Methotrexate—esophageal cancer	9.29e-05	0.00136	CcSEcCtD
Procarbazine—Fatigue—Methotrexate—esophageal cancer	9.21e-05	0.00135	CcSEcCtD
Procarbazine—Pain—Methotrexate—esophageal cancer	9.14e-05	0.00134	CcSEcCtD
Procarbazine—Vomiting—Capecitabine—esophageal cancer	9.12e-05	0.00134	CcSEcCtD
Procarbazine—Rash—Capecitabine—esophageal cancer	9.05e-05	0.00133	CcSEcCtD
Procarbazine—Dermatitis—Capecitabine—esophageal cancer	9.04e-05	0.00133	CcSEcCtD
Procarbazine—Headache—Capecitabine—esophageal cancer	8.99e-05	0.00132	CcSEcCtD
Procarbazine—XDH—Metabolism—SLC10A2—esophageal cancer	8.81e-05	0.00352	CbGpPWpGaD
Procarbazine—XDH—Metabolism—CA1—esophageal cancer	8.81e-05	0.00352	CbGpPWpGaD
Procarbazine—Feeling abnormal—Methotrexate—esophageal cancer	8.8e-05	0.00129	CcSEcCtD
Procarbazine—Gastrointestinal pain—Methotrexate—esophageal cancer	8.74e-05	0.00128	CcSEcCtD
Procarbazine—Nausea—Capecitabine—esophageal cancer	8.52e-05	0.00125	CcSEcCtD
Procarbazine—Urticaria—Methotrexate—esophageal cancer	8.49e-05	0.00124	CcSEcCtD
Procarbazine—Body temperature increased—Methotrexate—esophageal cancer	8.45e-05	0.00124	CcSEcCtD
Procarbazine—Abdominal pain—Methotrexate—esophageal cancer	8.45e-05	0.00124	CcSEcCtD
Procarbazine—XDH—Metabolism—CA2—esophageal cancer	8.06e-05	0.00322	CbGpPWpGaD
Procarbazine—Hypersensitivity—Methotrexate—esophageal cancer	7.87e-05	0.00115	CcSEcCtD
Procarbazine—Asthenia—Methotrexate—esophageal cancer	7.66e-05	0.00112	CcSEcCtD
Procarbazine—Pruritus—Methotrexate—esophageal cancer	7.56e-05	0.00111	CcSEcCtD
Procarbazine—XDH—Metabolism—PLCE1—esophageal cancer	7.49e-05	0.00299	CbGpPWpGaD
Procarbazine—XDH—Metabolism—ADH7—esophageal cancer	7.49e-05	0.00299	CbGpPWpGaD
Procarbazine—Diarrhoea—Methotrexate—esophageal cancer	7.31e-05	0.00107	CcSEcCtD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	7.16e-05	0.00286	CbGpPWpGaD
Procarbazine—Dizziness—Methotrexate—esophageal cancer	7.06e-05	0.00104	CcSEcCtD
Procarbazine—Vomiting—Methotrexate—esophageal cancer	6.79e-05	0.000996	CcSEcCtD
Procarbazine—Rash—Methotrexate—esophageal cancer	6.74e-05	0.000988	CcSEcCtD
Procarbazine—Dermatitis—Methotrexate—esophageal cancer	6.73e-05	0.000987	CcSEcCtD
Procarbazine—Headache—Methotrexate—esophageal cancer	6.69e-05	0.000981	CcSEcCtD
Procarbazine—XDH—Metabolism—ADH1B—esophageal cancer	6.57e-05	0.00262	CbGpPWpGaD
Procarbazine—Nausea—Methotrexate—esophageal cancer	6.35e-05	0.00093	CcSEcCtD
Procarbazine—XDH—Metabolism—TYMP—esophageal cancer	6.28e-05	0.0025	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	6.24e-05	0.00249	CbGpPWpGaD
Procarbazine—XDH—Metabolism—CYP26A1—esophageal cancer	6.11e-05	0.00244	CbGpPWpGaD
Procarbazine—XDH—Metabolism—ALOX15—esophageal cancer	5.95e-05	0.00237	CbGpPWpGaD
Procarbazine—XDH—Metabolism—GSTO1—esophageal cancer	5.68e-05	0.00227	CbGpPWpGaD
Procarbazine—XDH—Metabolism—TPI1—esophageal cancer	5.68e-05	0.00227	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—BLVRB—esophageal cancer	5.55e-05	0.00221	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—SLC52A3—esophageal cancer	5.55e-05	0.00221	CbGpPWpGaD
Procarbazine—XDH—Metabolism—ALDOB—esophageal cancer	5.44e-05	0.00217	CbGpPWpGaD
Procarbazine—XDH—Metabolism—GAPDH—esophageal cancer	5.24e-05	0.00209	CbGpPWpGaD
Procarbazine—XDH—Metabolism—CRABP1—esophageal cancer	5.19e-05	0.00207	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	4.96e-05	0.00198	CbGpPWpGaD
Procarbazine—XDH—Metabolism—GNG7—esophageal cancer	4.94e-05	0.00197	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—SLC10A2—esophageal cancer	4.72e-05	0.00188	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—CA1—esophageal cancer	4.72e-05	0.00188	CbGpPWpGaD
Procarbazine—XDH—Metabolism—ALDH2—esophageal cancer	4.63e-05	0.00185	CbGpPWpGaD
Procarbazine—XDH—Metabolism—GSTT1—esophageal cancer	4.4e-05	0.00176	CbGpPWpGaD
Procarbazine—XDH—Metabolism—CYP2A6—esophageal cancer	4.35e-05	0.00174	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—CA2—esophageal cancer	4.32e-05	0.00172	CbGpPWpGaD
Procarbazine—XDH—Metabolism—ENO1—esophageal cancer	4.12e-05	0.00165	CbGpPWpGaD
Procarbazine—XDH—Metabolism—PTGS1—esophageal cancer	4.12e-05	0.00165	CbGpPWpGaD
Procarbazine—XDH—Metabolism—PSME1—esophageal cancer	4.06e-05	0.00162	CbGpPWpGaD
Procarbazine—XDH—Metabolism—PSME2—esophageal cancer	4.06e-05	0.00162	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—ADH7—esophageal cancer	4.01e-05	0.0016	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—PLCE1—esophageal cancer	4.01e-05	0.0016	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.97e-05	0.00158	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—ADH1B—esophageal cancer	3.52e-05	0.0014	CbGpPWpGaD
Procarbazine—XDH—Metabolism—CYP1B1—esophageal cancer	3.51e-05	0.0014	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—TYMP—esophageal cancer	3.36e-05	0.00134	CbGpPWpGaD
Procarbazine—XDH—Metabolism—CYP19A1—esophageal cancer	3.3e-05	0.00132	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—CYP26A1—esophageal cancer	3.27e-05	0.00131	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—ALOX15—esophageal cancer	3.19e-05	0.00127	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—TPI1—esophageal cancer	3.04e-05	0.00121	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—GSTO1—esophageal cancer	3.04e-05	0.00121	CbGpPWpGaD
Procarbazine—XDH—Metabolism—HMOX1—esophageal cancer	3.01e-05	0.0012	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—ALDOB—esophageal cancer	2.92e-05	0.00116	CbGpPWpGaD
Procarbazine—XDH—Metabolism—ABCB1—esophageal cancer	2.89e-05	0.00115	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—GAPDH—esophageal cancer	2.81e-05	0.00112	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—CRABP1—esophageal cancer	2.78e-05	0.00111	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—GNG7—esophageal cancer	2.65e-05	0.00106	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—ALDH2—esophageal cancer	2.48e-05	0.000989	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—GSTT1—esophageal cancer	2.36e-05	0.000941	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—CYP2A6—esophageal cancer	2.33e-05	0.00093	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.32e-05	0.000926	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—ENO1—esophageal cancer	2.21e-05	0.000882	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—PTGS1—esophageal cancer	2.21e-05	0.000882	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—PSME2—esophageal cancer	2.18e-05	0.000869	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—PSME1—esophageal cancer	2.18e-05	0.000869	CbGpPWpGaD
Procarbazine—XDH—Metabolism—CREBBP—esophageal cancer	1.93e-05	0.00077	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.9e-05	0.000759	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—CYP19A1—esophageal cancer	1.77e-05	0.000705	CbGpPWpGaD
Procarbazine—XDH—Metabolism—NOS3—esophageal cancer	1.73e-05	0.00069	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—HMOX1—esophageal cancer	1.61e-05	0.000643	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.58e-05	0.000631	CbGpPWpGaD
Procarbazine—XDH—Metabolism—PTGS2—esophageal cancer	1.58e-05	0.000631	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—ABCB1—esophageal cancer	1.55e-05	0.000617	CbGpPWpGaD
Procarbazine—XDH—Metabolism—EP300—esophageal cancer	1.31e-05	0.000525	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.17e-05	0.000467	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—CREBBP—esophageal cancer	1.03e-05	0.000413	CbGpPWpGaD
Procarbazine—XDH—Metabolism—PIK3CA—esophageal cancer	9.72e-06	0.000388	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—NOS3—esophageal cancer	9.26e-06	0.000369	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—PTGS2—esophageal cancer	8.47e-06	0.000338	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—EP300—esophageal cancer	7.04e-06	0.000281	CbGpPWpGaD
Procarbazine—CYP1B1—Metabolism—PIK3CA—esophageal cancer	5.21e-06	0.000208	CbGpPWpGaD
